» Articles » PMID: 35263223

Induction of Broadly Neutralizing Antibodies Using a Secreted Form of the Hepatitis C Virus E1E2 Heterodimer As a Vaccine Candidate

Abstract

SignificanceHepatitis C virus chronically infects approximately 1% of the world's population, making an effective vaccine for hepatitis C virus a major unmet public health need. The membrane-associated E1E2 envelope glycoprotein has been used in clinical studies as a vaccine candidate. However, limited neutralization breadth and difficulty in producing large amounts of homogeneous membrane-associated E1E2 have hampered efforts to develop an E1E2-based vaccine. Our previous work described the design and biochemical validation of a native-like soluble secreted form of E1E2 (sE1E2). Here, we describe the immunogenic characterization of the sE1E2 complex. sE1E2 elicited broadly neutralizing antibodies in immunized mice, with increased neutralization breadth relative to the membrane-associated E1E2, thereby validating this platform as a promising model system for vaccine development.

Citing Articles

Virus-Mimicking Polymer Nanocomplexes Co-Assembling HCV E1E2 and Core Proteins with TLR 7/8 Agonist-Synthesis, Characterization, and In Vivo Activity.

Fuerst T, Marin A, Jeong S, Kulakova L, Hlushko R, Gorga K J Funct Biomater. 2025; 16(1).

PMID: 39852590 PMC: 11766188. DOI: 10.3390/jfb16010034.


Prokaryote- and Eukaryote-Based Expression Systems: Advances in Post-Pandemic Viral Antigen Production for Vaccines.

Khudainazarova N, Granovskiy D, Kondakova O, Ryabchevskaya E, Kovalenko A, Evtushenko E Int J Mol Sci. 2024; 25(22).

PMID: 39596049 PMC: 11594041. DOI: 10.3390/ijms252211979.


Hepatitis C Virus E1E2 Structure, Diversity, and Implications for Vaccine Development.

Pierce B, Felbinger N, Metcalf M, Toth E, Ofek G, Fuerst T Viruses. 2024; 16(5).

PMID: 38793684 PMC: 11125608. DOI: 10.3390/v16050803.


Establishment and methodological evaluation of a chemiluminescence assay for detection of anti-envelope protein (E1, E2) antibodies in the serum of hepatitis C virus-infected patients.

Wang N, Liu Q, Che F, Sun Q, Wang Y, Yang C J Clin Lab Anal. 2024; 38(4):e25011.

PMID: 38491776 PMC: 10943255. DOI: 10.1002/jcla.25011.


Influence of glycosylation on the immunogenicity and antigenicity of viral immunogens.

Newby M, Allen J, Crispin M Biotechnol Adv. 2023; 70:108283.

PMID: 37972669 PMC: 10867814. DOI: 10.1016/j.biotechadv.2023.108283.


References
1.
Buhler S, Bartenschlager R . Promotion of hepatocellular carcinoma by hepatitis C virus. Dig Dis. 2012; 30(5):445-52. DOI: 10.1159/000341688. View

2.
Li D, von Schaewen M, Wang X, Tao W, Zhang Y, Li L . Altered Glycosylation Patterns Increase Immunogenicity of a Subunit Hepatitis C Virus Vaccine, Inducing Neutralizing Antibodies Which Confer Protection in Mice. J Virol. 2016; 90(23):10486-10498. PMC: 5110194. DOI: 10.1128/JVI.01462-16. View

3.
de Jong Y, Dorner M, Mommersteeg M, Xiao J, Balazs A, Robbins J . Broadly neutralizing antibodies abrogate established hepatitis C virus infection. Sci Transl Med. 2014; 6(254):254ra129. PMC: 4312107. DOI: 10.1126/scitranslmed.3009512. View

4.
Keck Z, Li T, Xia J, Gal-Tanamy M, Olson O, Li S . Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. J Virol. 2008; 82(12):6061-6. PMC: 2395155. DOI: 10.1128/JVI.02475-07. View

5.
Sanders R, Derking R, Cupo A, Julien J, Yasmeen A, de Val N . A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 2013; 9(9):e1003618. PMC: 3777863. DOI: 10.1371/journal.ppat.1003618. View